cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes
- 15 April 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (8) , 2269-2277
Abstract
Purpose: To evaluate cMET (mesenchymal–epithelial transition factor gene) and phospho-cMET (p-cMET) levels in breast cancer subtypes and its impact on survival outcomes. Experimental Design: We measured protein levels of cMET and p-cMET in 257 breast cancers using reverse phase protein array. Regression tree method and Martingale residual plots were applied to find best cutoff point for high and low levels. Kaplan–Meier survival curves were used to estimate relapse-free (RFS) and overall (OS) survival. Cox proportional hazards models were fit to determine associations of cMET/p-cMET with outcomes after adjustment for other characteristics. Results: Median age was 51 years. There were 140 (54.5%) hormone receptor (HR) positive, 53 (20.6%) HER2 positive, and 64 (24.9%) triple-negative tumors. Using selected cutoffs, 181 (70.4%) and 123 (47.9%) cancers had high levels of cMET and p-cMET, respectively. There were no significant differences in mean expression of cMET (P < 0.128) and p-cMET (P < 0.088) by breast cancer subtype. Dichotomized cMET and p-cMET level was a significant prognostic factor for RFS [HR: 2.44, 95% confidence interval (CI): 1.34–4.44, P = 0.003 and HR: 1.64, 95% CI: 1.04–2.60, P = 0.033] and OS (HR: 3.18, 95% CI: 1.43–7.11, P = 0.003 and HR: 1.92, 95% CI: 1.08–3.44, P = 0.025). Within breast cancer subtypes, high cMET levels were associated with worse RFS (P = 0.014) and OS (P = 0.006) in HR-positive tumors, and high p-cMET levels were associated with worse RFS (P = 0.019) and OS (P = 0.014) in HER2-positive breast cancers. In multivariable analysis, patients with high cMET had a significantly higher risk of recurrence (HR: 2.06, 95% CI: 1.08–3.94, P = 0.028) and death (HR: 2.81, 95% CI: 1.19–6.64, P = 0.019). High p-cMET level was associated with higher risk of recurrence (HR: 1.79, 95% CI: 1.08–2.95.77, P = 0.020). Conclusions: High levels of cMET and p-cMET were seen in all breast cancer subtypes and correlated with poor prognosis. Clin Cancer Res; 18(8); 2269–77. ©2012 AACR.Keywords
This publication has 50 references indexed in Scilit:
- A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersClinical Proteomics, 2010
- Targeting the MET oncogene in cancer and metastasesExpert Opinion on Investigational Drugs, 2010
- The Met oncogene and basal-like breast cancer: another culprit to watch out for?Breast Cancer Research, 2010
- Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathwaysEuropean Journal of Cancer, 2010
- Targeting the HGF/Met signalling pathway in cancerEuropean Journal of Cancer, 2010
- Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissuesEuropean Journal of Cancer, 2010
- Expression and mutational analysis of MET in human solid cancersGenes, Chromosomes and Cancer, 2008
- Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19‐9 levels in pancreatic cancerProteomics, 2008
- Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature, 1987
- The human met oncogene is related to the tyrosine kinase oncogenesNature, 1985